Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Rigel Pharmaceuticals, Inc. (RIGL) -- Ignore unavailable to you. Want to Upgrade?

To: mcbio who wrote (402)	12/14/2008 11:21:06 AM
From: mopgcw	Read Replies (1) \| Respond to of 566

mexico results were higher, but the starting baseline was higher too, so they added an factor to make the results comparable to the US. this would seem to be valid, but gives a bit of complexity to the situation (then again, this work is never straight forward). in both countries the results were statistically significant, even with the adjustment to Mexico. Sorry I cant help with the exact comparison to Enbrel, but everything I have read indicates that R788 would be as efficacious, and as you note in pill form... So I think your analysis is on the right track. Keep in mind, I am a simple numbers guy, so my read of the science is limited. take care. George